The FDA has expanded approval for Moderna’s mRNA-based RSV vaccine based on Penn IP to include individuals aged 18-59 at increased risk. Read more here.
The FDA has expanded approval for Moderna’s mRNA-based RSV vaccine based on Penn IP to include individuals aged 18-59 at increased risk. Read more here.